Literature DB >> 3137398

Differentiation of human leukaemic cell lines and fresh leukaemia cells by low dose Ara-C: monitoring by expression of c-myc and c-fos oncogenes.

A Pinto1, V Attadia, R Rosati, G Colletta, R Cimino, A Colombatti.   

Abstract

The effects of low dose Ara-C on cellular oncogene expression were measured in HL-60 and U-937 cell lines and in primary cultures from leukaemic patients. Expression of c-myc was completely abolished in U-937 and greatly reduced in HL-60 after a 3 day exposure to the drug, whereas specific c-fos transcripts were increased. In fresh myeloid leukaemia samples, growth and DNA synthesis were reduced as in the two cell lines. Conversely, changes compatible with the induction of differentiation along the myelomonocytic pathway were much less pronounced than in cell lines treated with the same dose of Ara-C. Cells from one patient did not show any appreciable morphological change. The same sample displayed a greatly reduced expression of c-myc accompanied by a concurrent 10-fold increased expression of c-fos. The data suggest that the action of low dose Ara-C on oncogene expression is comparable to that of other differentiation-inducing agents that display both cytostatic and maturation promoting effects. Evaluation of cellular oncogene expression may therefore represent a useful tool for monitoring effects of low dose Ara-C on leukaemia cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137398     DOI: 10.1007/bf02985444

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  22 in total

1.  Primary activation of the vitellogenin gene in the rooster.

Authors:  R G Deeley; J I Gordon; A T Burns; K P Mullinix; M Binastein; R F Goldberg
Journal:  J Biol Chem       Date:  1977-11-25       Impact factor: 5.157

2.  Drug association including ara-C in myeloid leukemia cell differentiation: in vitro studies.

Authors:  C Chomienne; J P Abita; N Balitrand; L Degos
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

3.  Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.

Authors:  A ar-Rushdi; K Nishikura; J Erikson; R Watt; G Rovera; C M Croce
Journal:  Science       Date:  1983-10-28       Impact factor: 47.728

4.  Selective expression of fos proto-oncogene in human acute myelomonocytic and monocytic leukemias: a molecular marker of terminal differentiation.

Authors:  F Mavilio; U Testa; N M Sposi; M Petrini; E Pelosi; C Bordignon; S Amadori; F Mandelli; C Peschle
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

Review 5.  A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.

Authors:  B D Cheson; D M Jasperse; R Simon; M A Friedman
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544

6.  FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA.

Authors:  T Curran; G Peters; C Van Beveren; N M Teich; I M Verma
Journal:  J Virol       Date:  1982-11       Impact factor: 5.103

7.  Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug Harringtonine.

Authors:  A W Boyd; J R Sullivan
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

8.  c-fos oncogene expression in human hematopoietic malignancies is restricted to acute leukemias with monocytic phenotype and to subsets of B cell leukemias.

Authors:  A Pinto; G Colletta; L Del Vecchio; R Rosati; V Attadia; R Cimino; A Colombatti
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

9.  Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment.

Authors:  J A Coppola; M D Cole
Journal:  Nature       Date:  1986 Apr 24-30       Impact factor: 49.962

10.  Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia.

Authors:  T J Gonda; D Metcalf
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

View more
  1 in total

1.  Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb.

Authors:  M Caraglia; P Tagliaferri; P Correale; G Genua; A Pinto; S Del Vecchio; G Esposito; A R Bianco
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.